药物诱导的表观基因组可塑性重编程昼夜节律调控驱动前列腺癌走向雄激素非依赖
该研究对接受3个月恩杂鲁胺单药新辅助治疗的高危前列腺癌患者治疗前后组织行多组学分析,发现雄激素受体抑制驱动肿瘤向神经内分泌样状态转变,并诱导FOXA1从非活性染色质位点重编程至活性顺式调控元件,后者富集昼夜节律组分ARNTL,治疗后ARNTL水平与患者临床结局相关,ARNTL敲除强烈降低前列腺癌细胞生长。
要点
- 恩杂鲁胺治疗3个月诱导前列腺癌向神经内分泌样状态转变。
- 恩杂鲁胺诱导FOXA1从非活性染色质位点重编程至活性顺式调控元件。
- 治疗诱导的FOXA1位点富集昼夜节律组分ARNTL,治疗后ARNTL水平与临床结局相关。
核心结论
- 雄激素受体靶向治疗诱导FOXA1顺式调控组可塑性,使前列腺癌获得对昼夜节律调控因子ARNTL的依赖,ARNTL为候选治疗靶点。
研究设计与样本
- 对入组新辅助临床试验的高危前列腺癌患者,在恩杂鲁胺单药靶向治疗3个月前后分离组织行整合多组学分析。
主要发现
- 转录组分析显示雄激素受体抑制驱动肿瘤向神经内分泌样疾病状态转变。
- 表观基因组分析揭示恩杂鲁胺诱导先锋因子FOXA1从非活性染色质位点向决定促生存信号的活性顺式调控元件大规模重编程。
- 治疗诱导的FOXA1位点富集昼夜节律钟组分ARNTL,治疗后ARNTL水平与患者临床结局相关,ARNTL敲除强烈降低前列腺癌细胞生长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients' clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target. SIGNIFICANCE: Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development. See related commentary by Zhang et al., p. 2017. This article is highlighted in the In This Issue feature, p. 2007.
引用
- Linder S, Hoogstraat M, Stelloo S, et al. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discov. 2022. PMID: 35754340. doi:10.1158/2159-8290.CD-21-0576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。